HLN on NYSE

Haleon

Logo: Public domain, via Wikimedia Commons5

British multinational consumer healthcare company

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerHLN on NYSE1
  • IndustryPerfumes, Cosmetics & Other Toilet Preparations1
  • HeadquartersWeybridge1
  • Websitewww.haleon.com
  • Listed onLondon Stock Exchange (HLN), New York Stock Exchange (HLN)1
  • Incorporated inUnited Kingdom6
  • Business addressBuilding 5, First Floor, The Heights, Weybridge, X0 Kt13 0Ny6
  • Filer categoryLarge accelerated filer6
  • Legal formPublic Limited Company4
  • LEI549300PSB3WWEODCUP194
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressBUILDING 5, FIRST FLOOR, THE HEIGHTS, KT13 0NY Weybridge, United Kingdom4
  • Registered withCompanies House, 136912244

See how the biggest companies compare on our leaderboards

Brooklands office block, 22 July 2012 (2) (cropped)
Photo: Colin Smith, CC BY-SA 2.0, via Wikimedia Commons8

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in GBP, the currency the company reports in.

Key numbers, fiscal 2025

64.2%Gross margin9
21.9%Operating margin9
15.2%Net margin9
-1.8%Revenue growth, 20259
10.2%Return on equity9
0.47×Debt to equity9
2.3B GBPFree cash flow9

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Oral Health brought in 31% of the revenue Haleon broke down this way in fiscal 2025.

  1. Oral Health3.5B GBP931%up 4% from 2024
  2. Pain Relief2.6B GBP923%up 0% from 2024
  3. Respiratory Health1.9B GBP917%down 12% from 2024
  4. Vitamins, Minerals And Supplements1.7B GBP915%down 1% from 2024
  5. Digestive Health987.0M GBP99%down 4% from 2024
  6. Therapeutic Skin Health and Other460.0M GBP94%down 10% from 2024
Products and services by year
Products and services202320242025
Oral Health3.1B GBP3.3B GBP3.5B GBP
Pain Relief2.7B GBP2.6B GBP2.6B GBP
Respiratory Health2.2B GBP2.1B GBP1.9B GBP
Vitamins, Minerals And Supplements1.6B GBP1.7B GBP1.7B GBP
Digestive Health1.0B GBP1.0B GBP987.0M GBP
Therapeutic Skin Health and Other618.0M GBP510.0M GBP460.0M GBP

Business segments

EMEA And Latin America brought in 42% of the revenue Haleon broke down this way in fiscal 2025.

  1. EMEA And Latin America4.6B GBP942%down 1% from 2024
  2. North America3.9B GBP935%down 4% from 2024
  3. Asia Pacific2.6B GBP923%up 0% from 2024
Business segments by year
Business segments202320242025
EMEA And Latin America4.5B GBP4.6B GBP4.6B GBP
North America4.2B GBP4.0B GBP3.9B GBP
Asia Pacific2.6B GBP2.6B GBP2.6B GBP

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue36¢4.0B GBP
  • Research and development3¢316.0M GBP
  • Selling, general and admin39¢4.4B GBP
  • Interest3¢340.0M GBP
  • Income tax4¢472.0M GBP
  • Profit15¢1.7B GBP

Out of 11.0B GBP in revenue.9

Where each dollar of operating cash went, fiscal 2025

  • Capital spending12¢322.0M GBP
  • Share buybacks6¢170.0M GBP
  • Kept or used elsewhere81¢2.1B GBP

Out of 2.6B GBP of cash from operations.9

Financial statements

Revenue101112911.0B GBP in 2025+12% since 2020
05.0B GBP10.0B GBP15.0B GBP2020: 9.9B GBP9.9B GBP20202021: 9.5B GBP9.5B GBP2021−4%2022: 10.9B GBP10.9B GBP2022+14%2023: 11.3B GBP11.3B GBP2023+4%2024: 11.2B GBP11.2B GBP2024−1%2025: 11.0B GBP11.0B GBP2025−2%
Gross profit10111297.1B GBP in 2025+20% since 2020
02.0B GBP4.0B GBP6.0B GBP8.0B GBP2020: 5.9B GBP5.9B GBP20202021: 6.0B GBP6.0B GBP2021+1%2022: 6.6B GBP6.6B GBP2022+11%2023: 6.7B GBP6.7B GBP2023+3%2024: 6.8B GBP6.8B GBP2024+1%2025: 7.1B GBP7.1B GBP2025+4%
Operating income10111292.4B GBP in 2025+51% since 2020
01.0B GBP2.0B GBP3.0B GBP2020: 1.6B GBP1.6B GBP20202021: 1.6B GBP1.6B GBP2021+3%2022: 1.8B GBP1.8B GBP2022+11%2023: 2.0B GBP2.0B GBP2023+9%2024: 2.2B GBP2.2B GBP2024+11%2025: 2.4B GBP2.4B GBP2025+9%
Net income10111291.7B GBP in 2025+42% since 2020
0500.0M GBP1.0B GBP1.5B GBP2.0B GBP2020: 1.2B GBP1.2B GBP20202021: 1.4B GBP1.4B GBP2021+22%2022: 1.1B GBP1.1B GBP2022−22%2023: 1.1B GBP1.1B GBP2023−1%2024: 1.5B GBP1.5B GBP2024+33%2025: 1.7B GBP1.7B GBP2025+14%

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Revenue11.0B GBP11.2B GBP11.3B GBP
Cost of sales-4.0B GBP-4.4B GBP-4.6B GBP
Gross profit7.1B GBP6.8B GBP6.7B GBP
Selling, general and administration-4.4B GBP-4.5B GBP-4.4B GBP
Research and development-316.0M GBP-298.0M GBP-311.0M GBP
Other operating income/(expense)12.0M GBP132.0M GBP-27.0M GBP
Operating profit2.4B GBP2.2B GBP2.0B GBP
Finance income78.0M GBP82.0M GBP34.0M GBP
Finance expense-340.0M GBP-384.0M GBP-402.0M GBP
Net finance costs-262.0M GBP-302.0M GBP-368.0M GBP
Net monetary gain arising from hyperinflationary economies2.0M GBP6.0M GBP
Profit before tax2.2B GBP1.9B GBP1.6B GBP
Income tax-472.0M GBP-435.0M GBP-517.0M GBP
Profit after tax for the period1.7B GBP1.5B GBP1.1B GBP
Profit attributable to shareholders of the Group1.7B GBP1.4B GBP1.0B GBP
Profit attributable to non-controlling interests13.0M GBP33.0M GBP62.0M GBP
Basic earnings per share (pence)0.19 GBP0.16 GBP0.11 GBP
Diluted earnings per share (pence)0.18 GBP0.16 GBP0.11 GBP

Compare Haleon with another company

The story

GSK and Pfizer merged their consumer healthcare businesses in 2019. GSK owned just over two thirds of the joint venture, and Pfizer owned the remainder. Annual sales were around £10 billion across 120 markets in 2020. GSK then announced plans to spin off Haleon in 2022 to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division," according to Reuters. Unilever offered £50 billion for the business in 2022, which GSK rejected. Nestlé examined the possibility of a bid in conjunction with Reckitt. In October 2023, GSK reduced its ownership in Haleon to 7.4%, and in January 2024 it further reduced its ownership to 4.2%.

In August 2023, Haleon sold its Lamisil antifungal brand to Karo Healthcare AB for £235 million, and in February 2024, Haleon sold its ChapStick lip care brand to Yellow Wood Partners for £401 million.

In March 2024, Pfizer reduced its share in Haleon from 32% to 24% per cent by selling 630 million shares in a public offering.

Further sales followed: in April 2024, Haleon announced that it would close its Sensodyne toothpaste factory in Maidenhead, moving that manufacturing to Slovakia, and it outsourced mouthwash manufacturing to an unrelated company and, in September 2024, the company completed the sale of its non-US nicotine replacement therapy business to Dr. Reddy's Laboratories in a deal worth £458 million.

In March 2025, Pfizer sold its entire stake in Haleon for £2.5 billion ($3.24 billion), exiting the consumer healthcare business it helped create by its 2019 joint venture with GSK.

From Wikipedia’s article on Haleon, shared under CC BY-SA 4.0.7

Products and brands

Operations

Oral health accounted for 28.5 percent of revenue in 2021.

Sir Dave Lewis is chairman, with Brian McNamara as chief executive.

Brands

Current

Brands include:

From Wikipedia’s article on Haleon, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries

  • Haleon Czech Republic

From Wikidata.1

Former names

  • DRVW 2022 LtdDec 23, 2021 to Feb 15, 20226

Timeline

  1. Oct 20, 2021Founded Haleon is founded4

Filings

522 filings to the SEC since October 2021: 5 annual reports, 27 large holders, 490 other. The latest 20:

  1. Oct 1, 20266-K TOTAL VOTING RIGHTS AND CAPITAL EDGAR
  2. Sep 24, 20266-K DIRECTOR/PDMR SHAREHOLDING EDGAR
  3. Sep 18, 20266-K DIRECTOR/PDMR SHAREHOLDING EDGAR
  4. Sep 1, 20266-K TOTAL VOTING RIGHTS AND CAPITAL EDGAR
  5. Aug 26, 2026CERT NYSE CERTIFICATION EDGAR
  6. Aug 21, 20268-A12B EDGAR
  7. Aug 21, 20266-K EDGAR
  8. Aug 19, 20266-K CASH TENDER OFFER - PRICING, EXPIRATION AND RESULT EDGAR
  9. Aug 19, 20266-K TRANSACTIONS IN OWN SHARES & BUYBACK UPDATE EDGAR
  10. Aug 17, 20266-K TRANSACTIONS IN OWN SHARES EDGAR
  11. Aug 13, 20266-K LAUNCH & PRICE: $2BN THREE-TRANCHE BOND OFFERING EDGAR
  12. Aug 13, 2026424B5 EDGAR
  13. Aug 13, 2026FWP EDGAR
  14. Aug 11, 20266-K CASH TENDER OFFER FOR OUTSTANDING 2027 3.375% FIXED RATE NOTES EDGAR
  15. Aug 11, 20266-K CASH TENDER OFFER - OUTSTANDING 2027 3.375% NOTES EDGAR
  16. Aug 11, 2026424B5 EDGAR
  17. Aug 11, 2026POSASR EDGAR
  18. Aug 3, 20266-K TOTAL VOTING RIGHTS AND CAPITAL EDGAR
  19. Jul 30, 20266-K 2026 HALF YEAR RESULTS EDGAR
  20. Jul 30, 20266-K/A EDGAR

The 522 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Dodge & Cox149,934,507$1.4B0.7%+3,394,844
Fmr LLC120,991,250$1.1B0.0%+7,022,091
Clearbridge Investments, LLC32,342,126$301.8M0.2%+623,401
Morgan Stanley19,461,762$181.6M0.0%+295,509
Harris Associates L P16,833,252$157.1M0.2%+1,801,211
Harding Loevner LP15,414,796$147.8M1.4%−297,754
Nuveen, LLC15,332,859$143.1M0.0%+6,633,766
Arrowstreet Capital, Limited Partnership14,181,817$132.3M0.1%−492,701
Bank Of America Corp /de/10,850,097$101.2M0.0%−84,131
Jpmorgan Chase & Co10,824,395$101.0M0.0%+2,544,927
Point72 Asset Management, L.P.9,264,255$86.4M0.1%+2,690,217
First Eagle Investment Management, LLC8,449,712$78.8M0.1%+4,417,069
Raymond James Financial Inc7,278,875$67.9M0.0%+1,014,834
Norges Bank7,175,000$66.9M0.0%New
Aristotle Capital Management, LLC7,090,436$66.2M0.1%−573,078
Jones Financial Companies Lllp7,116,095$65.8M0.0%−1,970,433
Douglas Lane & Associates, LLC6,692,390$62.4M0.8%−1,393
Envestnet Asset Management Inc6,276,154$58.6M0.0%−758,624
Goldman Sachs Group Inc5,394,442$50.3M0.0%−733,010
Wells Fargo & Company/mn4,924,330$45.9M0.0%+901,581
Voloridge Investment Management, LLC4,783,989$44.6M0.2%+3,116,495
Bank Julius Baer & Co. Ltd, Zurich4,481,615$41.8M0.1%+125,239
BlackRock, Inc.3,977,539$37.1M0.0%−1,273,418
Northern Trust Corp3,965,011$37.0M0.0%−916,326
CIBC Bancorp USA Inc.3,856,063$36.0M0.0%−97,450

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

14 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 23, 2025Val T. HoyleDemocratic, HouseSale$1,001 - $15,000+5.1%Report
Jul 10, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000+25.0%Report
Jun 24, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000−32.4%Report
Apr 9, 2025Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+37.7%Report
Oct 29, 2024Val T. HoyleDemocratic, HouseBuy$1,001 - $15,000−32.3%Report
Jun 21, 2024Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+25.8%Report
May 20, 2024Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−28.8%Report
Jul 21, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−58.9%Report
Jul 20, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−57.1%Report
Jul 19, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−54.9%Report
Jul 10, 2023Daniel S. GoldmanDemocratic, HouseSale$15,001 - $50,000+53.1%Report
Mar 31, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−66.4%Report
Feb 27, 2023Daniel S. GoldmanDemocratic, HouseBuy$1,001 - $15,000−68.5%Report
Jan 13, 2023Daniel S. GoldmanDemocratic, HouseBuy$1,001 - $15,000−69.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16